Product Description
Mechanisms of Action: Inorganic Phosphate Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ineos Healthcare Limited
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hyperphosphatemia|Kidney Failure, Chronic
Phase 2: Kidney Failure, Chronic|Hyperphosphatemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00358722 |
ALCON | P2 |
Terminated |
Kidney Failure, Chronic |
2008-05-01 |
2019-03-21 |
Treatments |
|
NCT00436683 |
ACT3 | P2 |
Completed |
Kidney Failure, Chronic|Hyperphosphatemia |
2008-01-01 |
2019-03-21 |
Treatments |
|
NCT00317694 |
IH 001 (ACT 2) | P2 |
Completed |
Kidney Failure, Chronic|Hyperphosphatemia |
2007-06-01 |
2019-03-21 |
Treatments |
|
NCT00844662 |
ACT 402 | P3 |
Terminated |
Kidney Failure, Chronic|Hyperphosphatemia |
2011-09-01 |
2019-03-18 |
||
2008-004729-41 |
2008-004729-41 | P3 |
Completed |
Hyperphosphatemia |
2011-07-27 |
2022-03-12 |
Treatments |
|
2008-004730-25 |
2008-004730-25 | P3 |
Terminated |
Unknown |
2010-03-31 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|